Current Advances in Hematologic Malignancies

Dear Colleagues,

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system, which affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML)), myeloma, and lymphoma (Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL)). Acute myeloid leukemia (AML) is a rare but catastrophic disease with a high mortality rate, predominantly occurring in the elderly.

Hematological malignancies account for ~10% of newly diagnosed cancers each year, with lymphomas being more common than leukemias and melanoma. Aberrant genetic, metabolic, and epigenetic events promote oncogenic transformation. Although the standard of chemotherapy treatment has not changed significantly over the past few decades, the overall understanding of the biology and pathology of hematological cancers has greatly improved due to the emergence of next-generation technologies. The development of new targeted therapies, including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody–drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells, has improved the clinical outcomes for blood cancers.

In the present Special Issue, we will highlight the recent advances in understanding of the molecular and cellular biology and pathophysiology of hematologic malignancies, and how these developments drive us towards a new therapeutic landscape in the near future.

Dr. Upendar Rao Golla
Dr. Ilyas Chachoua
Dr. Anna Eiring
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• leukemia
• acute lymphocytic leukemia (ALL)
• chronic lymphocytic leukemia (CLL)
• acute myeloid leukemia (AML)
• chronic myeloid leukemia (CML)
• myeloma
• lymphoma
• Hodgkin's lymphoma (HL)
• non-Hodgkin's lymphoma (NHL)
• next-generation sequencing
• signaling pathways
• leukemia stem cells
• non-coding RNAs
• genetics
• genomics
• epigenetics
• cancer metabolism
• chromatin architecture